NEW THIS MONTH
**NEW**
10th
Annual Meeting Photo Gallery
**NEW**
10th
Annual International Meeting Contributed Paper Award Recipients
**NEW**
Value in Health Vol. 8 No. 3 (May/June 2005) (Annual Meeting Abstract
Issue now includes research papers)
**NEW**
Value In Health Features
New “On-Line Early” Manuscripts
**NEW**
New ISPOR Student Network Chair
**NEW**
ISPOR Special Interest Group (SIG) Updates
**NEW**
7 New Positions at the ISPOR website
ISPOR ONGOING ACTIVITIES
1.
Publications
2.
Meetings and Congresses
3.
Educational Activities
4.
Student News
5.
ISPOR Special Interest Groups
6.
Committee and Task Force Activities
7.
Hot Topics
8.
Important Dates to Remember
8.
Asia Consortium and Local
Chapter News
10. Employment in Pharmacoeconomics and Outcomes Research
11.
Membership
- PUBLICATIONS
Top
VALUE IN HEALTH
**NEW** Value in Health: Volume 8, Issue 3, May/June 2005 is online at:
http://www.ispor.org/valueinhealth_index.asp.
The following is the TABLE OF CONTENTS for Value in Health Volume 8, Issue 3,
May/June 2005:
FORWARD
Josephine Mauskopf
EMPIRICAL
Cost-Effectiveness of Face-to-Face Smoking Cessation
Interventions: A Dynamic Modeling Study
Talitha L. Feenstra, Heleen H. Hamberg-van Reenen, Rudolf T.
Hoogenveen, Maureen P.M.H. Rutten-van Molken
Economic and Utilization Outcomes
Associated with Choice of Treatment for Venous Thromboembolism in Hospitalized
Patients
Kevin K. Knight, John Wong, Ole Hauch, Gail Wygant, Daniel
Aguilar, Joshua J. Ofman
Managing Prices for Hospital
Pharmaceuticals: A Successful Strategy for New Zealand?
June M. Tordoff, Pauline T. Norris, David M. Reith
The Economic Value of Childhood
Varicella Vaccination in France and Germany
Laurent Coudeville, Alain Brunot, Thomas D. Szucs, Benoit
Dervaux
POLICY AND APPLICATION
Federal Sponsorship of
Cost-Effectiveness and Related Research in Health Care: 1997-2001
Joanna E. Siegel, Sepheen C. Byron, William F. Lawrence
CONTRIBUTED PODIUM
PRESENTATIONS
Value in Health; Volume 8, Issue 3,
Page 237
CONTRIBUTED POSTER PRESENTATIONS
Value in Health; Volume 8, Issue 3, Page 258
DISCLOSURE INFORMATION
Value in Health; Volume 8, Issue 3, Page 420
ABSTRACTS INDEX
Volume in Health; Volume 8, Issue 3, Page 426
**NEW** VALUE IN HEALTH FEATURES NEW “ON-LINE EARLY”
MANUSCRIPTS
Beginning with Volume 8, Issue 4 of Value in Health, our
"On-Line Early" format will be featured.
Available later this month, this new feature will allow you
to view articles from upcoming issues approximately 1
month before their scheduled issue release date. To view
these "On-Line Early" articles, simply
go to
http://www.ispor.org/valueinhealth_index.asp,
log on using your membership information,
and follow the link.
Featured in Volume 8, Issue 4…
EMPIRICAL
OVERACTIVE BLADDER/URINARY INCONTINENCE (OAB/UI) DRUG
THERAPY DISCONTINUATION MAY SIGNIFICANTLY INCREASES THE RISK OF URINARY TRACT
INFECTION IN CHRONIC OAB/UI PATIENTS
Yanni F. Yu, Michael B.
Nichol, Andrew P. Yu, and Jeonghoon Ahn
Overactive bladder and urinary incontinence are conditions
referring to any
bladder dysfunction of storing and voiding urine. They can be transient but millions of patients,
especially seniors and females, are suffering from a chronic OAB/UI. Drug
therapy has been a popular treatment option for OAB/UI patients but compliance and persistence during
the course of drug therapy has been a major issue in treating OAB/UI. A recent study, “Persistence and Adherence of Medications for Chronic Overactive Bladder/Urinary Incontinence in
the California Medicaid program” published in Value in Health, reports that, among
the chronic OAB/UI patients, the patients who discontinued drug therapy have
significantly higher risk of having an incidence of urinary tract infection
(UTI) than who did not. The researchers of the University of Southern California looked at 2,496 randomly selected chronic OAB/UI patients in California
Medicaid (MediCal) program for compliance patterns and associated clinical
outcomes. “We found that the patients who discontinued OAB/UI drug therapy have
37% higher risk of UTI incidence in six-month follow-up period,” says Jeonghoon
Ahn, the corresponding author of this research. He emphasized that the persistence
and treatment discontinuation are big problems for the OAB/UI patients not only
in terms of UTI incidence but also in terms of many other negative impacts.
HIGHER QUETIAPINE DOSES MAY BE MORE EFFECTIVE
Frank Gianfrancesco, Ruey-hua Wang MS, and Jacqueline Pesa
Quetiapine, an atypical antipsychotic, is an effective and
well tolerated agent for the treatment of schizophrenia and acute
mania associated with bipolar disorder. However, broad dosage
guidelines may have encouraged quetiapine initiation schedules that are too
conservative to be optimally effective. This possibility was investigated in a
recent study, “Relationship between initial quetiapine dose and effectiveness
as reflected in subsequent mental health service use among patients with
schizophrenia or bipolar disorder,” published in Value and Health, Volume
8, Issue 4. Using a large commercial claims database and controlling for
patient differences, Gianfrancesco et al., of HECON Associates and AstraZeneca,
found that patients initiated on higher doses of quetiapine had lower
subsequent levels of mental health service use. Hospitalizations were mainly
affected among schizophrenia patients while bipolar patients experienced
reduced ambulatory services. Consistent with these findings, patients started
on higher doses were also less likely to require later upward dose adjustments.
Large numbers of both schizophrenia and bipolar patients were given quetiapine
doses that were below the lowest recommended level (150 mg/d). While the study
does not and cannot identify appropriate quetiapine dosage levels for
commercially insured patients (who may be less severely ill), it does suggest
that more aggressive dosing may be more effective.
HEALTH CARE COST, QUALITY, AND OUTCOMES: ISPOR BOOK OF TERMS
"The ISPOR Book of Terms has been a real hit
with our customers and employees alike. It fills a gap for those who are
new to Outcomes." Jenifer Ehreth, PhD, Director Reimbursement for Europe, Middle East and Africa Medtronic Europe
This ISPOR publication includes more than 100 detailed
monographs covering over 400 terms used in health care delivery, management,
and regulation, as well as health care outcomes research including clinical,
economic, and quality-of-life research terms. ISPOR member discounted price is $36.00;
a 40% discount! Student/Library/Academic discounted price: $33.00
(a 45% discount). On-line ordering is now available at:
http://www.ispor.org/publications/lexicon_index.asp.
Contact Stephen Priori at
spriori@ispor.org for information on
orders over 100.
- ISPOR MEETINGS AND CONGRESSES
Top
ISPOR EIGHT ANNUAL
EUROPEAN CONGRESS
6-8
November 2005 Palazzo Degli Affari, Florence , Italy
"INCORPORATING
VALUES INTO HEALTH CARE DECISIONS"
**Abstract Submission
Deadline: 20 June 2005
June 20 at 11:59 PM US Pacific Daylight Savings Time is the
deadline to submit an abstract for presentation at the ISPOR 8th Annual
European Congress. All abstract submissions are online:
http://www.ispor.org/congresses/italy1105/abstr_instr.asp
Contributed Research topics:
**Clinical Outcomes Studies
**Cost Studies
**Patient Reported
Outcomes Studies (Quality of Life, Utility, Treatment/Patient/Work
Satisfaction, Preference Studies)
**Health Care Use & Policy Studies
**Method Studies & Concepts
Contributed Workshop topics:
**Clinical study methodology issues including
pharmacoepidemiology
**Cost study methodology issues
**Quality of life study
methodology issues including patient reported outcomes
**Preference-based studies methodology issues
including utility studies
**Drug/device coverage research issues
**Health care policy development issues using
outcomes research
**Risk assessment/risk management issues
**Compliance issues
**Patient registry development issues
Contributed Issue Panel
Submissions are accepted on (but not excluded
to) the following topics:
**Pharmacoeconomic / Health Economic Study
Methodology Issues
**Quality of Life / Patient-Reported Outcomes
Study Methodology Issues
**Utility (Preference-based) Study Methodology
Issues
**Clinical Outcomes
**Health Policy
**Health Care Reimbursement / Coverage Issues
**Risk Assessment Study Issues
**Use of Health Economic/Pharmacoeconomic
Information by Decision-Makers
First Plenary Session:
Patient Values and Societal Values: How to Measure and
Compare Outcomes
and What Considerations for the Different Audiences
http://www.ispor.org/congresses/italy1105/100605.asp
Second Plenary Session:
Health Care Decision Makers Facing the Budget Allocation
Dilemma:
Compressing Mortality vs. Compressing Morbidity
http://www.ispor.org/congresses/italy1105/100705.asp
Third Plenary Session:
The Value of Safety: A Critical Issue All Along the
Development
and Marketing of Pharmaceuticals
http://www.ispor.org/congresses/italy1105/100805.asp
Exhibitor Opportunities available at:
https://www.ispor.org/Exhibit_Sponsor/ExhibitorOpportunities.aspx?event=3
Sponsorship Opportunities available at:
https://www.ispor.org/Exhibit_Sponsor/SponsorshipOpportunities.aspx?event=3
For more details about the Congress, go to:
http://www.ispor.org/congresses/italy1105/index.asp
ISPOR 10TH ANNUAL INTERNATIONAL MEETING–RECORD
ATTENDANCE!!
May 15-18, 2005, Marriott Wardman Park Hotel, Washington, DC, USA
Celebrating 10 years of global
pharmacoeconomics awareness, the ISPOR Annual International Meeting celebrated
it’s 10th anniversary at the Marriot Wardman Park Hotel, in the
nation’s capitol, Washington, DC, USA, and once again successful. Over 1300
attendees from 33 different countries joined in a week’s-long worth of
festivities, as well as participated in the technical sessions and scientific
matter in which attendees have grown accustomed to at ISPOR Annual
International Meetings.
**NEW** Photo Gallery
http://www.ispor.org/meetings/washington0505/pg/pages/index.html
- EDUCATION ACTIVITIES
Top
ISPOR SHORT COURSES–ISPOR 8TH ANNUAL EUROPEAN
CONGRESS
13 ISPOR SHORT COURSES prior to the ISPOR 8th
Annual European Congress 6-8 November NOW available at:
http://www.ispor.org/congresses/italy1105/index.asp
ISPOR Distance Learning Program Modules
http://www.ispor.org/distancelearning/index.asp
The following module topics are currently available (total
of 40 modules):
·
Pharmacoeconomics
·
Pharmacoeconomic
Evaluations & Methods
·
Cost-Effectiveness
Analysis
·
Cost-Benefit
Analysis
·
Cost-Utility
Analysis
·
Patient-Reported
Outcomes (Utilities, Health-Related Quality Of Life, Treatment Satisfaction,
Treatment Adherence, Patient Preferences)
·
Study Design in
Pharmacoeconomics
·
Guidelines
and Reference Standards
·
Pharmacoeconomics
in Drug Development, Reimbursement and Marketing
- STUDENT NEWS
Top
**NEW** ISPOR STUDENT NETWORK CHAIR
Josh Epstein, BA, BS, The University of Southern California, Los Angels, CA USA, is the newly elected chair for the Student Network for 2005-2006.
For more details on the ISPOR
Student Network, please visit:
http://www.ispor.org/student/student_index.asp
- ISPOR SPECIAL INTEREST GROUPS (SIG)
Top
VALUE-BASED REIMBURSEMENT SIG
The Value-based Reimbursement SIG held an Open Meeting for
all interested ISPOR members and a breakfast for SIG leadership members during
the ISPOR 10th Annual International Meeting. The mission, working groups,
leadership and future activities of the SIG were presented during the meeting
while the breakfast was an opportunity for the Working Group Chair people to
meet with leadership members, formulate their plans and define the tasks needed
to reach their goals.
UPCOMING: This SIG is planning an event for the ISPOR 8th
Annual European Congress.
UPCOMING: Each of the working groups is
holding a teleconference in the 2nd or 3rd week of June
with their members.
Value Based Reimbursement SIG Working Groups:
· Evidence and Payer Decision-making Working Group
Co-Chair: Nancy Risebrough Senior Associate, HOPE Research Centre, Toronto, Ontario, Canada
Co-Chair: Michael Halpern MD, MPH, PhD, Chief Scientist,
Exponent, Alexandria, VA, USA
· Global Reimbursement Strategies
Working Group
Co-Chair: Geoffrey Wilson DPhil, BSc, MSc, PhD, Managing Director,
ValuemoniX, Penn, UK
Co-Chair: Jennifer Stephens PharmD, Senior Clinical Consultant,
PharMerit, Bethesda, MD USA
· Global Reimbursement Trends Working
Group
Co-Chair: Stefan Holmstrom BSc, MSc, Manager, Strategic Pricing & Reimbursement, Allergan,
Biot, France
Co-Chair: Kevin Mayo PhD, Head, Global Strategic Pricing & Health
Economics (NS & ID), Novartis Pharmaceuticals, Basel, Switzerland
· Reimbursement Literature Working
Group
Co-Chair: Paul Trueman MA, Sales & Marketing Director, York Health
Economics Consortium, University of York, Heslington, York, UK
Co-Chair: Parthiv Mahadevia MD, MPH, Associate Director, Payment and
Coverage Group, Amgen, Inc., Washington, DC, USA
· Payer-oriented Evidence Guidelines
Working Group
Co-Chair: James Mackay MD, Medical Director, Providence Health Plans, Beaverton, OR, USA
Co-Chair: Joseph Singer MD, Vice President, HealthCore, Inc, Wilmington,
DE, USA
For more details on this SIG or to join as a reference or
leadership group member, please visit:
http://www.ispor.org/sigs/reimbursement.asp
HEALTH TECHNOLOGY ASSESSMENT SIG
The Health Technology Assessment SIG held an Open Meeting
for all interested ISPOR members and a breakfast for SIG leadership members
during the ISPOR 10th Annual International Meeting. The mission, working groups,
leadership and future activities of the SIG were presented during the meeting
while the breakfast was an opportunity for the Working Group Chair people to
meet with leadership members, formulate their plans and define the tasks needed
to reach their goals.
UPCOMING: This SIG is planning an event for the ISPOR 8th
Annual European Congress.
UPCOMING: Each of the working groups is holding a teleconference in
the 2nd or 3rd week of June with their members.
HTA SIG
Working Groups:
*HTA Methodology Working Group
Chair: Francis
Pang BSc, MSc, PhD, Head
of Health Economics, Abbott Laboratories, Maidenhead, UK
*HTA in Reimbursement Economics Working
Group
Co-Chair: Jalpa Doshi PhD, Health Services Research
Scientist, General Internal Medicine, University of Pennsylvania, Philadelphia,
PA USA
Co-Chair: Bonnie Handke RN, Sr. Reimbursement Manager, Medtronic,
Minneapolis, MN, USA
*Applied HTA Working Group
Co-Chair: Uwe Siebert MD, MPH, MSc, Director, Cardiovascular Research
Program, MGH Institute for Technology Assessment, Harvard Medical School, Boston,
MA, USA
Co-Chair: Philip Booth MS, Director of Health Technology Appraisal,
Novartis Pharmaceuticals, Frimley, Camberley, UK
*HTA to Support Marketing Initiatives Working Group
Co-Chair: Sheryl Szeinbach BS, MS, PhD, RPh, Professor, College of Pharmacy, Ohio State University, Columbus, OH, USA
Co-Chair: Noreen Sullivan BS, Vice President, Aequitas, San Diego, CA, USA
For more details on this SIG, please visit:
http://www.ispor.org/sigs/hta.asp
CLINICAL PRACTICE SIG
***NEW*** SIG Chair: Peter K. Wong PhD, MBA, RPh, Vice President, Clinical
Effectiveness & PI, Good Samaritan Hospital, Dayton, OH, USA
UPCOMING: Look for new developments with this SIG.
The Clinical
Practice SIG held a forum during the ISPOR 10th Annual International Meeting. The topic was Applying
Pharmacoeconomic Principles in Clinical Practice . . . Noble Enterprise or Pipe
Dream?
and
the Value Proposition to Payers & Providers: Do Pharmacoeconomic
Studies Meet the Needs of Decision Makers?
Stakeholder perspectives (payer, hospital and individual provider) were
presented as well as real-world examples of how outcomes research and
pharmacoeconomic principles are applied across different medical centers, in
Pharmacy & Therapeutics Committees and how patient outcomes can be used to
develop practice guidelines and evaluate treatment outcomes. An
audience discussion about restrictions that currently prevent the widespread
usage of outcomes research and pharmacoeconomics in decision making along with
suggested measures to take to change the current situation closed the session.
Clinical Practice SIG also held a workshop. The topic was Standardized Reporting Format for Outcomes Research or
Economic Evaluation and a System to Measure the Strength of Evidence of Studies
If you would like to get involved in this SIG, please review
this webpage and join as a leadership group or reference group member.
http://www.ispor.org/sigs/cp.asp
PATIENT REGISTRY SIG
Patient Registry SIG held a forum
during the ISPOR 10th Annual International Meeting. The topic was Patient Registries: Opportunity and Responsibility. Key
issues, including the industry's role in sponsoring post-approval registries
that capture "real world" clinical, economic, and humanistic data and
other evaluations critical for a more accurate characterization of how drugs
and devices are utilized in actual medical practice, were discussed. In
addition, the findings from the Patient Registry survey were presented and the
Working Group Chairs commented on issues involving commercialization, safety
surveillance, analytical methods, technology, and global initiatives.
UPCOMING: The PR SIG Working Groups are moving forward with their best practices
/ guidance White Paper drafts. If you would like to get more involved, please
review the webpage below and join as a reference group or leadership group
member
http://www.ispor.org/sigs/patient_registr.asp
QUALITY OF LIFE SIG
**NEW** SIG Chair: Judith Barr ScD, Med, Associate Professor, School of
Pharmacy, Northeastern University & Director, National Education and
Research Center for Outcomes Assessment, Boston, MA, USA
The Quality of Life SIG held a forum during the ISPOR Annual
Meeting. The topic
was: Health Status and Patient Reported Outcomes / Quality of Life Measures in
the ‘Real World' Included in the discussion: Benefits of Using ‘Real
World' Quality of Life/Patient Reported Outcomes, Challenges and Limitations of
‘Real World' Quality of Life/Patient Reported Outcomes, Methods and Best
Practices for ‘Real World' Quality of Life/Patient Reported Outcomes Studies,
and Next Steps for ISPOR
The Quality of Life SIG also held an Open Meeting. The mission, working groups,
leadership and future activities of the SIG were presented.
If you would like to get more involved with this SIG and a
working group, please review the webpage below and contact the SIG Chair,
Judith Barr at
j.barr@neu.edu.
For more details on this SIG, please visit:
http://www.ispor.org/sigs/qol.asp
MEDICATION COMPLIANCE SIG
Three successful workshops were presented at the ISPOR 10th
Annual International Meeting by the Medication Compliance SIG. The Chairs and
Leadership Group members also participated in working breakfasts and dinners
during the Meeting, further progressing the goals of this SIG.
The Medication Compliance Forum during the 10th
Annual International Meeting was well attended. The progress and future goals
of the four working groups: Issues & Methods WG; Analyses Standards WG;
Education Working Group; and Economics of Medications Compliance WG were
presented and discussed, followed by discussion and questions.
UPCOMING:
Workshops will be presented at the 8th European Congress
If you would like to join this SIG as a leadership group or
reference group member please e-mail
medcomsig@ispor.org
For more details on this SIG, please visit:
http://www.ispor.org/sigs/medication.asp
RETROSPECTIVE DATABASE SIG
The Retrospective Database SIG held its first Forum at the
ISPOR 10th International Meeting in Washington, DC on Tuesday, May
17 to present ISPOR Digest of International Databases questionnaire form and to
get feedback from the audience. The Working Groups also participated in
breakfasts to discuss the goals of the SIG.
For more details on this SIG, please visit:
http://www.ispor.org/sigs/retrospective_db.asp
RISK MANAGEMENT SIG
The Risk
Management SIG presented two workshops during the ISPOR 10th Annual
International Meeting.
The first workshop topic was balancing risks and benefits of healthcare
treatments in the 21st century. Areas of risk/benefit assessment
were explored and how to balance the two. An interactive group case study
was performed following the presentation.
The second workshop topic was ISPOR member perspectives: How
do individuals perceive risks and benefits of pharmaceuticals in comparison
with other non-medical activities. This workshop exposed and analyzed the results of a
healthcare survey given to ISPOR membership. Interesting findings
included: US v. non-US comparisons of risk assessment and the amount of effect
that individual side-effect experiences had on the perception of risk
associated with other pharmaceuticals.
For more details on this SIG, please
visit:
http://www.ispor.org/sigs/rm.asp
and join as a reference or leadership group member.
MANAGED CARE SIG
For more details, please visit:
http://www.ispor.org/sigs/mc_pbm.asp
Special
Interest Group membership is open to ALL ISPOR members. To JOIN any SIG:
http://www.ispor.org/sigs/joinsig.htm
- ISPOR BOARD, COMMITTEE, AND TASK FORCE ACTIVITIES
Top
AWARD COMMITTEE ACTIVITIES
**NEW** ISPOR TENTH ANNUAL INTERNATIONAL MEETING
CONTRIBUTED PAPER AWARDS RECIPIENTS
BEST CONTRIBUTED PAPER AWARDS PODIUM PRESENTATIONS
GENERAL
MS3
ECONOMIC EVALUATION OF CONTROLLED-RELEASE OXYCODONE
(OXYCONTIN® TABLETS) (CRO) VERSUS OXYCODONE/ACETAMINOPHEN (PERCOCET®)
(OXY/APAP) FOR OSTEOARTHRITIS PAIN OF THE HIP OR KNEE
Marshall DA1, Strauss ME2, Pericak D1,
Buitendyk M1, Codding C3, Kim S2, Torrance G1,
1Innovus Research Inc, Burlington, ON, Canada; 2Purdue
Pharma L.P, Stamford, CT, USA; 3Oklahoma Sports, Oklahoma City, OK,
USA
IN1
COMPARISON OF RISK FACTORS FOR BLOOD STREAM CANDIDEMIA AND
BACTEREMIA IN HOSPITALIZED PATIENTS
Amrutkar PP, Rege M, Kumar N, Kachroo S, Garey KW
University of Houston, College of Pharmacy, Houston, TX, USA
QL2
NEW WEIGHTS FOR OLD: A SCALE OF VALUES FOR EQ-5D HEALTH
STATES
Kind P, Macran S, Hennessy S
University of York, York, UK
NEW INVESTIGATOR
HP4
POTENTIALLY INAPPROPRIATE MEDICATION PRESCRIBING FOR ELDERLY
AMBULATORY PATIENTS IN REGIONE EMILIA ROMAGNA, ITALY
Maio V, Yuen EJ, Novielli KD, Rabinowitz C, Louis DZ
Jefferson Medical College, Philadelphia, PA, USA
MS4
THE COST-EFFECTIVENESS OF ADDING INFLIXIMAB TO USUAL THERAPY
IN THE TREATMENT OF PSORIATIC ARTHRITIS
Marra CA1, Maetzel A2, Farewell VT3, Rashidi
AA1, Shi P1, Antoni C4, Wong JB5,
Gladman DD6
1University of British Columbia, Vancouver, BC, Canada; 2Toronto
General Research Institute, Toronto, ON, Canada; 3Institute of
Public Health, Cambridge, UK; 4Schering-Plough Corporation,
Kenilworth, NJ, USA; 5Tufts-New England Medical Center, Boston, MA,
USA; 6Toronto Western Research Institute, Toronto, ON, Canada
IN4
COST EFFECTIVENESS OF HIV TREATMENT INNOVATIONS OF GREATER
EFFICACY THAN HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)
Snedecor SJ1, Hartzema A1, Schiller KC2
1Pharmacy Health Care Administration, Gainesville, FL, USA; 2University of Florida, Gainesville, FL, USA
STUDENT
CN3
ONCOLOGISTS' COST-EFFECTIVENESS THRESHOLDS FOR NEW CANCER
THERAPIES
Nadler E1, Eckert B2, Neumann P2
1Dana Farber Cancer Institute, Boston, MA, USA; 2HarvardUniversity,
Boston, MA, USA
MH4
EFFECT OF SECOND-GENERATION ANTIDEPRESSANT DISCONTINUATION
ON DEPRESSIVE RELAPSE IN ADULT PATIENTS WITH BIPOLAR DEPRESSION
Fu AZ, Christensen DB, Hansen RA
University of North Carolina, Chapel Hill, NC, USA
CS8
ECONOMIC EVALUATION OF ONDANSETRON VERSUS DIMENHYDRINATE FOR
PREVENTION OF POSTOPERATIVE VOMITING IN CHILDREN
Piwko C1, Lasry A1, Alanezi K1, Coyte
PC1, Ungar WJ2
1University of Toronto, Toronto, ON, Canada; 2The Hospital for Sick Children, Toronto, ON, Canada
BEST CONTRIBUTED PAPER AWARDS POSTER
PRESENTATIONS
GENERAL
PCN1
META-ANALYSIS OF THE DIAGNOSTIC ACCURACY OF SCREENING TESTS
FOR COLORECTAL CANCER
Slivinskas JC1, Gagnon YM1, Levy AR2,
Enns RA3
1 Oxford Outcomes, Vancouver, BC, Canada; 2 University of
British Columbia, Vancouver, BC, Canada; 3 St. Paul's Hospital, UBC,
Vancouver, BC, Canada
PHP49
BRIEF SUMMARY FORMATS OF DTCA TO IMPROVE CONSUMER
COMPREHENSION
Sansgiry SS, Kawatkar AA
University of Houston, Houston, TX, USA
PHP34
AN ASSESSMENT OF THE ASSOCIATION BETWEEN UNDERLYING WORKER
MEDICAL CONDITIONS AND WORKER ABSENTEEISM IN THE US
Mavros P1, Pietri G2
1 Merck & Co., Inc, Whitehouse Station, NJ, USA; 2 Rutgers University, Piscataway, NJ, USA
NEW INVESTIGATOR
PDB46
WILLINGNESS-TO-PAY FOR INHALED INSULIN – A CANADIAN
PERSPECTIVE
Sadri H
Health Outcome and Pharmacoeconomics Research Centre, Toronto, ON, Canada
PDB25
DEPRESSION IN PATIENTS WITH TYPE 2 DIABETES: IMPACT ON
UTILIZATION PATTERNS AND ADHERENCE TO ORAL HYPOGLYCEMIC AGENTS
Kalsekar I1, Madhavan SM2, Amonkar M3, Douglas S2,
Makela E2, Scott V2
1 Butler University, Indianapolis, IN, USA; 2 West
Virginia University, Morgantown, WV, USA; 3 GlaxoSmithKline,
Collegeville, PA, USA
PCV16
INCREMENTAL EFFECTS OF CONCURRENT PHARMACOTHERAPEUTIC
REGIMENS FOR HEART FAILURE ON HOSPITALIZATIONS AND COSTS
Skrepnek GH1, Abarca J1, Malone DC1, Armstrong EP1,
Shirazi FM2, Woosley RL2
1 University of Arizona College of Pharmacy, Tucson, AZ, USA; 2
University of Arizona College of Medicine, Tucson, AZ, USA
STUDENT
PCV33
MONITORING OF LIPID LEVELS AND ADVERSE EVENTS AMONG TEXAS MEDICAID PATIENTS ON STATIN THERAPY
Dastani H1, Shepherd M1, Sasane R2
1 University of Texas, Austin, TX, USA; 2 AstraZeneca
Pharmaceuticals LP, Wilmington, DE, USA
PDB45
QUALITY OF LIFE (SF12), CLINICAL OUTCOMES, AND COMORBID
CONDITIONS IN PATIENTS WITH TYPE-2 DIABETES: A POPULATION STUDY
Sundaram M, Kavookjian J
West Virginia University, Morgantown, WV, USA
PCN2
SURVIVAL ANALYSIS OF PAIN RELIEF PROVIDED BY DOXEPIN ORAL
RINSE FOR ORAL MUCOSITIS PATIENTS
Epstein JD1, Epstein JB2, Epstein MS3, Oien HJ4,
Truelove EL5
1 University of Southern California, Los Angeles, CA, USA; 2
University of Illinois, Chicago, IL, USA; 3 Fred Hutchison Cancer
Research Center, Seattle, WA, USA; 4 Private General Dental
Practice, Tualatin, OR, USA; 5 University of Washington, Seattle,
WA, USA
2005 ISPOR SCIENTIFIC AWARDEES:
http://www.ispor.org/awards/index_.asp
2005 ISPOR SERVICE AWARDEES:
http://www.ispor.org/awards/service/service.asp
2005 ISPOR DISTINGUISHED SERVICE
AWARDEES:
http://www.ispor.org/awards/service/distinguish.asp
ISPOR TASK FORCE: USING "REAL WORLD"
DATA IN COVERAGE AND REIMBURSEMENT DECISIONS
For more details, including a draft outline of this final
paper, and a list of core group members, go to:
http://www.ispor.org/workpaper/real_world_data.asp
- HOT TOPICS
Top
PRESCRIPTION
DRUG PURCHASING SIMPLIFIED THROUGH NEW TECHNOLOGIES
CMS AWARDS
CONTRACT FOR NEW SYSTEMS TO COORDINATE BENEFICIARY COVERAGE
May 23, 2005 – The
Centers for Medicare & Medicaid Services (CMS) has taken another step to
make it easier for Medicare beneficiaries to get prescription drugs from their
local pharmacies. This action will allow pharmacists to use their existing
computer systems to determine which Medicare drug plan to bill and whether the
beneficiary has other drug coverage, all while the beneficiary is at the
counter. Medicare beneficiaries will begin to receive their prescription drugs
under the new benefit starting January 1, 2006.
For full text of the
article, see:
http://www.cms.hhs.gov/media/press/release.asp?Counter=1466
- IMPORTANT DATES TO REMEMBER
Top
June 20, 2005 – Abstract Submission deadline for the ISPOR
8th Annual European Congress.
1 July 2005 – Abstract Submission begins for the ISPOR 2nd
Asia-Pacific Congress.
8-11 November 2005 – ISPOR 8th European
Congress, Palazzo Degli Affari, Florence, Italy
5-7 March 2006 – ISPOR 2nd Asia-Pacific
Conference, Shanghai Worldfield Convention Hotel, Shanghai, China
20-26 May 2006 – ISPOR 11th Annual
International Meeting, Marriott Philadelphia, Philadelphia, PA
- ASIA CONSORTIUM
AND LOCAL CHAPTER NEWS
Top
ISPOR ASIA CONSORTIUM
For more details on this consortium, please visit:
http://www.ispor.org/consortiums/asia.asp
For more details on ISPOR local chapters, please visit:
http://www.ispor.org/local_chapters/index.asp
ISPOR 2ND ASIA-PACIFIC CONFERENCE
The ISPOR 2nd Asia-Pacific Conference will be held in Shanghai, China, 5-7 March 2006. Abstract submission begins 1 July 2005 and ends 3 October 2005.
Early registration deadline is 5 February 2006.
For more details on the 2nd Asia-Pacific
Conference, please visit:
http://www.ispor.org/conferences/shanghai0306/index.asp
- EMPLOYMENT
Top
**NEW** 7 NEW POSITIONS AT THE ISPOR
WEBSITE:
http://www.ispor.org/employment/employment_index.asp
Advertise your positions on ISPOR Website (~1 million
hits per month)
INTERNSHIPS
Visit ISPOR's Internship-Professional
Recruitment Assistance Program (I-PRAP) at
http://www.ispor.org/iprap/index.asp
STUDENTS: Post your CVs/resumes
for employers to view and search for internship positions available. Nine
student resumes posted!
EMPLOYERS: Post your Intern
positions for FREE and access CVs/resumes from students.
If you have any questions, please
contact:
iprap@ispor.org.
- ISPOR
MEMBERSHIP
Top
Update your email address at
https://www.ispor.org/members/addresschange.asp!
Your email address is required as part of your log in information in the
members only section of the ISPOR website.
